

TABLE 198: WITHDRAWAL DUE TO ADVERSE EVENT

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	n	N	%
Andreone et al., 2014 PEARL-II	1b	(14) PAR/RIT12 + OMB12 + DAS12	0	95	0%
Dieterich et al., 2014-2+3+4	1	(68) SIM12 PR48	1	53	2%
Gane et al., 2013-2 ELECTRON	1	(3) SOF12 + RBV12	0	10	0%
Gane et al., 2014-2 ELECTRON	1	(10) SOF12 + LDV12 + RBV12	0	9	0%
Gane et al., 2014-3 ELECTRON	1	(10) SOF12 + LDV12 + RBV12	0	9	0%
Forns et al., 2014 PROMISE	1	(1) PR48	0	133	0%
		(42) SIM12 PR24-48 RGT	1	260	0%
Jacobson et al., 2013 FUSION	2+3	(3) SOF12 + RBV12	0	103	0%
Lawitz et al., 2014	2+3	(40) SOF12 + PR12	1	47	2%
Lawitz et al., 2014 LONESTAR	1	(6) SOF12 + LDV12	0	19	0%
		(10) SOF12 + LDV12 + RBV12	0	21	0%
Lawitz et al., 2014 COSMOS	1	(5) SIM12 + SOF12	0	14	0%
		(72) SOF12 + SIM12 + RBV12	0	27	0%
Osinusi et al., 2014 SYNERGY	1	(6) SOF12 + LDV12	0	14	0%
Pol et al., 2015	1	(40) SOF12 + PR12	0	80	0%
Reddy et al., 2015 ATTAIN	1	(39) T12 PR48 q8	4	384	1%
		(68) SIM12 PR48	0	379	0%
Sulkowski et al., 2014-3	2+3	(4) SOF24 + RBV24	0	41	0%
Wyles et al., 2015	1	(10) SOF12 + LDV12 + RBV12	0	51	0%
Zeuzem et al., 2011 REALIZE	1	(1) PR48	2	132	2%
		(39) T12 PR48 q8	1	266	0%
Zeuzem et al., 2014 ASPIRE	1	(1) PR48	0	66	0%
		(68) SIM12 PR48	1	66	2%

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; b.i.d. = twice daily; CrI = credible interval; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir; SOF = sofosbuvir; T = telaprevir; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.